Unum Therapeutics Lands $12,000,000 Series A Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e31f7a52-dcef-447e-a90c-b65df9bb0eb3
Date
10/22/2014
Company Name
Unum Therapeutics
Mailing Address
One Broadway 4th Floor Cambridge, MA 02142 USA
Company Description
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer.
Website
http://www.unumrx.com
Transaction Type
Venture Equity
Transaction Amount
$12,000,000
Transaction Round
Series A
Proceeds Purposes
Unum plans to use capital raised through this financing to advance its lead candidate through initial proof-of-concept clinical studies, further enhance the ACTR technology, and establish partnerships to access tumor-specific antibodies for a pipeline of novel combination therapies.
M&A Terms
Venture Investor
Venture Investor
Venture Investor